Report cover image

Osteoporosis Drugs Market, Size, Share, Global Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

Publisher Renub Research
Published Aug 01, 2023
Length 115 Pages
SKU # RNBR18142894

Description

Osteoporosis Drugs Market, Size, Share, Global Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis


Osteoporosis drugs market is projected to value US$ 17.52 Billion by the year 2030, according to Renub research. Osteoporosis persists undetected and untreated in at-risk groups despite the availability of several prescription drugs, acknowledged risk assessment techniques, and diagnostic criteria. The field of clinical research on osteoporosis has a wonderful chance to help patients with improved and more affordable medicines. One in three women and one in five men throughout the world are at risk of osteoporotic fractures. This ailment affects more than 200 million individuals globally. In the United States and Europe, osteoporosis affects about 30% of postmenopausal women. Unexpectedly, the rates of treatment start remain unexpectedly low, ranging from 5% to 30%, despite the availability of several authorized drugs for osteoporosis and even after the incidence of verified osteoporotic fractures.

A decline in bone mass and density is a symptom of osteoporosis. The bones get weaker as a result and break more easily. The aging population, rising awareness, improved treatment options, and cost-effectiveness drive the need for osteoporosis drugs in response to the increased risk of osteoporosis. The availability of effective drugs makes treatment more accessible, and their cost-effectiveness compared to fracture expenses highlights their importance in managing the condition. Asian and white women are the most susceptible. Surprisingly, because there is no specific alternative to treating osteoporosis (such as surgery), the Osteoporosis Drugs industry is a necessary component of osteoporosis treatment everywhere.

Osteoporosis drugs market is anticipated to grow at a CAGR of 3.98% during 2022–2030

The availability of various effective osteoporosis drugs has improved accessibility to treatment, moving beyond the limitations of hormone replacement therapy (HRT), which is no longer recommended due to associated cancer risks. The development of new drugs like bisphosphonates and teriparatide has enhanced treatment effectiveness and safety. Osteoporosis drugs are also cost-effective compared to the expenses associated with fractures, which can be financially burdensome.

There is a growing focus on innovative drug delivery systems, aiming to enhance efficacy, safety, and patient convenience. Extensive research and development efforts are underway in the osteoporosis drug market, exploring new medications, delivery systems, and diagnostic and treatment approaches. However, cost, side effects, adherence, effectiveness variation, and lack of awareness pose barriers to Osteoporosis Drugs Market; ongoing research offers hope for improved drugs. As a result, the global osteoporosis drug market will reach US$ 12.82 Billion in 2022.

Global market for generic osteoporosis drugs is expected to expand due to patent expiration, rising awareness, and supportive government policies
By Type, the global osteoporosis drug market is divided into Branded and Generic. With the expiration of patents on branded drugs, the availability of generic versions is on the rise, resulting in substantial price reductions. Increased awareness of cost-effective generic drugs among patients and healthcare professionals drives their growing popularity in Osteoporosis Drugs Market due to lower prices and the absence of research and patent costs. Government policies that encourage the use of generics, such as requirements in public hospitals and clinics, further drive down prices and increase demand.

Branded drugs, protected by patents, enjoy advantages over generic drugs due to marketing, brand loyalty, and government regulations. Branded drugs are heavily promoted, increasing awareness and influencing prescriptions. Patients may prefer familiar branded drugs, even if generics are available. Some countries have regulations limiting generic drug availability. Despite higher prices, branded drugs may offer unique benefits. Consultation with a doctor is essential when deciding between branded and generic drugs.

Rank Ligand Inhibitors (RANKL) are projected to have a significant market share in the global osteoporosis market

Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others are the drug classes present in the global osteoporosis drug market. RANKL inhibitors, like denosumab (Prolia), effectively reduce fracture risk in osteoporosis. Though generally safe, RANKL inhibitors may have mild side effects such as fatigue, headaches, and back pain, as well as rare but serious side effects like osteonecrosis of the jaw (ONJ). Patent protection and marketing efforts give RANKL inhibitors an advantage over other osteoporosis drugs, and brand loyalty may influence patient preference.

Bisphosphonates, such as alendronate (Fosamax), are effective in reducing the risk of fractures in people with osteoporosis. A study published in The New England Journal of Medicine found that bisphosphonates decreased the risk of hip fractures by 50% in women with osteoporosis. The patent protection and marketing efforts of bisphosphonate manufacturers contribute to their higher market shares compared to other osteoporosis drugs, despite the availability of generic equivalents.

Oral administration is the preferred and most convenient route for most people due to its ease and avoidance of injections or infusions

Oral, Injectable, and Others are the routes of administration present in the global osteoporosis market. Oral drugs are cost-effective and safe, but they may cause mild side effects, including rare serious effects like osteonecrosis of the jaw. In terms of effectiveness, oral medications have proven to be successful in treating osteoporosis, as demonstrated by alendronate's (Fosamax) ability to reduce the risk of hip fractures by 50%. Patients commonly prefer oral drugs due to their convenience and the avoidance of injections or infusions, as indicated by studies focusing on patient preferences.

Injectable drugs like denosumab (Prolia) are effective and provide immediate effects for treating osteoporosis. Though generally safe, they can cause mild side effects and rare serious effects like osteonecrosis of the jaw (ONJ). Patent protection ensures exclusivity and higher prices. Injectable drug manufacturers invest in marketing, influencing prescriptions. Brand loyalty drives Osteoporosis Drugs Market, despite other options.

Online pharmacies are the fastest-growing segment of the global osteoporosis market due to their convenience, affordability, variety, privacy, and 24/7 availability.

By Distribution Channel, the global osteoporosis drugs market is segmented into Hospital pharmacies, Retail pharmacies, and online pharmacies. Hospital pharmacies have advantages in administering injectable osteoporosis drugs due to their expertise, patient support, and cost-effectiveness. Complex dosing regimens are better managed by hospital pharmacists, who can educate and monitor patients. They offer convenience and lower costs thanks to their larger buying power and government regulations.

Although hospital pharmacies currently dominate the Osteoporosis Drugs Market, patients have a convenient and cost-effective alternative for ordering osteoporosis medications through online pharmacies. By taking advantage of reduced costs and a wide range of brand-name and generic medications, patients can find affordable solutions. Furthermore, the privacy policies and round-the-clock accessibility of internet pharmacies have enhanced the overall experience for patients.

United States has leadership in the global osteoporosis drug market

The United States, Canada, France, Germany, Italy, Spain, the United Kingdom, Belgium, the Netherlands, China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, Turkey, the UAE, and Rest of World are the countries constituting the global osteoporosis drug market. In the United States, osteoporosis is a significant problem due to the large aging population. In addition to the roughly 10 million people who already suffer from the illness, an additional 44 million Americans have low bone mass.

Osteoporosis is well understood in the country, which increases the need for treatments and pharmaceuticals. The United States, which has a robust research and development sector, has seen major investments in Osteoporosis Drugs Market research from top pharmaceutical companies. The population high disposable earnings enable them to be able to afford osteoporosis drugs and therapies, unlike other countries where reliance on government programs or charitable organizations may be necessary. The majority of health insurance plans in the United States include osteoporosis, ensuring greater access to essential care.

Key Players

Companies participating in the global osteoporosis drugs market include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis International AG, Merck & Co. Inc., and Amgen Inc.

In August 2021, The Medicine Controller General of India (DCGI) granted Enzene Biosciences Ltd. marketing authorization (MA) for denosumab, a biosimilar medicine used to treat osteoporosis in adults.

Renub Research latest report “Global Osteoporosis Drugs Market, Type (Branded and Generic), Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), Route of Administration (Oral, Injectable, and Others), Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), Countries (United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, Turkey, UAE, and ROW), Companies (Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Novartis International AG, Merck & Co. Inc., and Amgen Inc.)” provides a detailed analysis of Global Osteoporosis Drugs Market.

Types – Global Osteoporosis Drugs Market has been covered from 2 viewpoints:

1. Branded
2. Generic

Drug Class – Global Osteoporosis Drugs Market has been covered from 6 viewpoints:

1. Bisphosphonates
2. Selective Estrogen Inhibitors Modulator (SERM)
3. Parathyroid Hormone Therapy
4. Calcitonin
5. Rank Ligand Inhibitors
6. Others

Route of Administration – Global Osteoporosis Drugs Market has been covered from 3 viewpoints:

1. Oral
2. Injectable
3. Others

Distribution Channels – Global Osteoporosis Drugs Market has been covered from 3 viewpoints:

1. Hospital pharmacies
2. Retail pharmacies
3. Online pharmacies

Countries – Global Osteoporosis Drugs Market has been covered from 26 viewpoints:

1 North America

1.1 United States
1.2 Canada

2 Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherland

3 Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 Australia
3.5 South Korea
3.6 Thailand
3.7 Malaysia
3.8 Indonesia
3.9 New Zealand

4 Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5 Middle East & Africa

5.1 South Africa
5.2 Saudi Arabia
5.3 Turkey
5.4 UAE

6 Rest of the World

Company Insights:

• Overview
• Recent Development
• Financial Insight

Company Analysis:

1. Eli Lilly and Company
2. Pfizer Inc.,
3. F. Hoffmann-La Roche
4. Teva Pharmaceutical Industries Ltd.,
5. GlaxoSmithKline plc.,
6. Novartis International AG
7. Merck & Co. Inc.
8. Amgen Inc.

Table of Contents

115 Pages
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Osteoporosis Drugs Market
6. Market Share – Global Osteoporosis Drugs Market
6.1 By Type
6.2 By Drug Class
6.3 By Route of Administration
6.4 By Distribution Channel
6.5 By Countries
7. Type – Global Osteoporosis Drugs Market
7.1 Branded
7.2 Generic
8. Drug Class – Global Osteoporosis Drugs Market
8.1 Bisphosphonates
8.2 Selective Estrogen Inhibitors Modulator (SERM)
8.3 Parathyroid Hormone Therapy
8.4 Calcitonin
8.5 Rank Ligand Inhibitors
8.6 Others
9. Route of Administration – Global Osteoporosis Drugs Market
9.1 Oral
9.2 Injectable
9.3 Others
10. Distribution Channel-Global Osteoporosis Drugs Market
10.1 Hospital Pharmacies
10.2 Retail Pharmacies
10.3 Online Pharmacies
11. Countries-Global Osteoporosis Drugs Market
11.1 North America
11.1.1 United States
11.1.2 Canada
11.2 Europe
11.2.1 France
11.2.2 Germany
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Belgium
11.2.7 Netherland
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 Australia
11.3.5 South Korea
11.3.6 Thailand
11.3.7 Malaysia
11.3.8 Indonesia
11.3.9 New Zealand
11.4 Latin America
11.4.1 Brazil
11.4.2 Mexico
11.4.3 Argentina
11.5 Middle East & Africa
11.5.1 South Africa
11.5.2 Saudi Arabia
11.5.3 Turkey
11.5.4 UAE
11.6 Rest of the World
12. Porter’s Five Forces Analysis - Global Osteoporosis Drugs Market
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Rivalry
12.4 Threat of New Entrants
12.5 Threat of Substitutes
13. SWOT Analysis - Global Osteoporosis Drugs Market
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threat
14. Key Players Analysis
14.1 Eli Lilly and Company
14.1.1 Overview
14.1.2 Recent Development
14.1.3 SWOT Analysis
14.1.4 Financial Insight
14.2 Pfizer Inc.
14.2.1 Overview
14.2.2 Recent Development
14.2.3 SWOT Analysis
14.2.4 Financial Insight
14.3 F. Hoffmann-La Roche
14.3.1 Overview
14.3.2 Recent Development
14.3.3 SWOT Analysis
14.3.4 Financial Insight
14.4 Teva Pharmaceutical Industries Ltd.
14.4.1 Overview
14.4.2 Recent Development
14.4.3 SWOT Analysis
14.4.4 Financial Insight
14.5 GlaxoSmithKline plc.
14.5.1 Overview
14.5.2 Recent Development
14.5.3 SWOT Analysis
14.5.4 Financial Insight
14.6 Novartis International AG
14.6.1 Overview
14.6.2 Recent Development
14.6.3 SWOT Analysis
14.6.4 Financial Insight
14.7 Merck & Co. Inc.
14.7.1 Overview
14.7.2 Recent Development
14.7.3 SWOT Analysis
14.7.4 Financial Insight
14.8 Amgen Inc.
14.8.1 Overview
14.8.2 Recent Development
14.8.3 SWOT Analysis
14.8.4 Financial Insights
List of Figures:
Figure-01: Global – Osteoporosis Drugs Market (Billion US$), 2018 – 2022
Figure-02: Global – Forecast for Osteoporosis Drugs Market (Billion US$), 2022 – 2030
Figure-03: Type – Branded Market (Billion US$), 2018 – 2022
Figure-04: Type – Forecast for Branded Market (Billion US$), 2022 – 2030
Figure-05: Type – Generic Market (Billion US$), 2018 – 2022
Figure-06: Type – Forecast for Generic Market (Billion US$), 2022 – 2030
Figure-07: Drug Class – Bisphosphonates Market (Billion US$), 2018 – 2022
Figure-08: Drug Class – Forecast for Bisphosphonates Market (Billion US$), 2022 – 2030
Figure-09: Drug Class – Selective Estrogen Inhibitors Modulator (SERM) Market (Million US$), 2018 – 2022
Figure-10: Drug Class – Forecast for Selective Estrogen Inhibitors Modulator (SERM) Market (Million US$), 2022 – 2030
Figure-11: Drug Class – Parathyroid Hormone Therapy Market (Billion US$), 2018 – 2022
Figure-12: Drug Class – Forecast for Parathyroid Hormone Therapy Market (Billion US$), 2022 – 2030
Figure-13: Drug Class – Calcitonin Market (Million US$), 2018 – 2022
Figure-14: Drug Class – Forecast for Calcitonin Market (Million US$), 2022 – 2030
Figure-15: Drug Class – Rank Ligand Inhibitors Market (Billion US$), 2018 – 2022
Figure-16: Drug Class – Forecast for Rank Ligand Inhibitors Market (Billion US$), 2022 – 2030
Figure-17: Drug Class – Others Market (Billion US$), 2018 – 2022
Figure-18: Drug Class – Forecast for Others Market (Billion US$), 2022 – 2030
Figure-19: Route of Administration – Oral Market (Billion US$), 2018 – 2022
Figure-20: Route of Administration – Forecast for Oral Market (Billion US$), 2022 – 2030
Figure-21: Route of Administration – Injectable Market (Billion US$), 2018 – 2022
Figure-22: Route of Administration – Forecast for Injectable Market (Billion US$), 2022 – 2030
Figure-23: Route of Administration – Others Market (Million US$), 2018 – 2022
Figure-24: Route of Administration – Forecast for Others Market (Million US$), 2022 – 2030
Figure-25: Distribution Channel – Hospital Pharmacies Market (Million US$), 2018 – 2022
Figure-26: Distribution Channel – Forecast for Hospital Pharmacies Market (Million US$), 2023 – 2030
Figure-27: Distribution Channel – Retail Pharmacies Market (Million US$), 2018 – 2022
Figure-28: Distribution Channel – Forecast for Retail Pharmacies Market (Million US$), 2023 – 2030
Figure-29: Distribution Channel – Online Pharmacies Market (Million US$), 2018 – 2022
Figure-30: Distribution Channel – Forecast for Online Pharmacies Market (Million US$), 2023 – 2030
Figure-31: United States – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-32: United States – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-33: Canada – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-34: Canada – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-35: France – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-36: France – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-37: Germany – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-38: Germany – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-39: Italy – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-40: Italy – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-41: Spain – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-42: Spain – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-43: United Kingdom – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-44: United Kingdom – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-45: Belgium – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-46: Belgium – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-47: Netherland – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-48: Netherland – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-49: China – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-50: China – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-51: Japan – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-52: Japan – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-53: India – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-54: India – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-55: Australia – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-56: Australia – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-57: South Korea – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-58: South Korea – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-59: Thailand – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-60: Thailand – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-61: Malaysia – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-62: Malaysia – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-63: Indonesia – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-64: Indonesia – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-65: New Zealand – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-66: New Zealand – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-67: Brazil – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-68: Brazil – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-69: Mexico – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-70: Mexico – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-71: Argentina – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-72: Argentina – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-73: South Africa – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-74: South Africa – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-75: Saudi Arabia – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-76: Saudi Arabia – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-77: Turkey – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-78: Turkey – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-79: UAE – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-80: UAE – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-81: Rest of the World – Osteoporosis Drugs Market (Million US$), 2018 – 2022
Figure-82: Rest of the World – Forecast for Osteoporosis Drugs Market (Million US$), 2023 – 2030
Figure-83: Eli Lilly and Company – Global Revenue (Billion US$), 2018 – 2022
Figure-84: Eli Lilly and Company – Forecast for Global Revenue (Billion US$), 2022 – 2030
Figure-85: Pfizer Inc. – Global Revenue (Billion US$), 2018 – 2022
Figure-86: Pfizer Inc. – Forecast for Global Revenue (Billion US$), 2022 – 2030
Figure-87: F. Hoffmann-La Roche – Global Revenue (Billion US$), 2018 – 2022
Figure-88: F. Hoffmann-La Roche – Forecast for Global Revenue (Billion US$), 2022 – 2030
Figure-89: Teva Pharmaceutical Industries Ltd. – Global Revenue (Billion US$), 2018 – 2022
Figure-90: Teva Pharmaceutical Industries Ltd. – Forecast for Global Revenue (Billion US$), 2022 – 2030
Figure-91: GlaxoSmithKline plc. – Global Revenue (Billion US$), 2018 – 2022
Figure-92: GlaxoSmithKline plc. – Forecast for Global Revenue (Billion US$), 2022 – 2030
Figure-93: Novartis International AG – Global Revenue (Billion US$), 2018 – 2022
Figure-94: Novartis International AG – Forecast for Global Revenue (Billion US$), 2022 – 2030
Figure-95: Merck & Co. Inc. – Global Revenue (Billion US$), 2018 – 2022
Figure-96: Merck & Co. Inc. – Forecast for Global Revenue (Billion US$), 2022 – 2030
Figure-97: Amgen Inc. – Global Revenue (Billion US$), 2018 – 2022
Figure-98: Amgen Inc. – Forecast for Global Revenue (Billion US$), 2022 – 2030
List of Tables:
Table-01: Global – Osteoporosis Drugs Market Share by Type (Percent), 2018 – 2022
Table-02: Global – Forecast for Osteoporosis Drugs Market Share by Type (Percent), 2022 – 2030
Table-03: Global – Osteoporosis Drugs Market Share by Drug Class (Percent), 2018 – 2022
Table-04: Global – Forecast for Osteoporosis Drugs Market Share by Drug Class (Percent), 2022 – 2030
Table-05: Global – Osteoporosis Drugs Market Share by Route of Administration (Percent), 2018 – 2022
Table-06: Global – Forecast for Osteoporosis Drugs Market Share by Route of Administration (Percent), 2022 – 2030
Table-07: Global – Osteoporosis Drugs Market Share by Distribution Channel (Percent), 2018 – 2022
Table-08: Global – Forecast for Osteoporosis Drugs Market Share by Distribution Channel (Percent), 2022 – 2030
Table-09: Global – Osteoporosis Drugs Market Share by Countries (Percent), 2018 – 2022
Table-10: Global – Forecast for Osteoporosis Drugs Market Share by Countries (Percent), 2022 – 2030

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us